Evicita · Supplement evidence, graded and cited · Supplements · Lifestyle · Mechanisms · Lab tests · 中文

Huperzine A

Huperzine A (Huperzia serrata extract) · also known as Huperzine A, Huperzine A

Huperzine A is a reversible acetylcholinesterase (AChE) inhibitor. After oral dosing in humans, red blood cell AChE activity is measurably suppressed. In vitro it can block the NMDA channel, but the concentrations needed are far above human plasma levels, so an NMDA effect at usual doses has not been confirmed.

Typical dose: 50–200 mcg/day, taken in the morning. The unit is micrograms (mcg), so take care not to overdose.
Absorption and forms: It is absorbed fairly quickly after oral dosing. The half-life in humans varies by study and formulation and is about 5–12 hours, not 12–24 hours as a general rule. Doses are measured in micrograms (mcg), so they must be measured precisely. A cycle of 5 days on and 2 days off has no reliable basis.

Clinical uses and human evidence

Age-related cognitive decline

Mixed resultsGrade B · Moderate evidence
Studies (2)
  1. Yang 2013 · PLoS One · Meta-analysis · n=1823 — Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
  2. Rafii 2011 · Neurology · RCT · n=210 — A phase II trial of huperzine A in mild to moderate Alzheimer disease

Memory

Mixed resultsGrade C · Preliminary evidence
Studies (1)
  1. Sun 1999 · Zhongguo Yao Li Xue Bao · RCT · n=68 — Huperzine-A capsules enhance memory and learning performance in 34 pairs of matched adolescent students

Mechanisms of action

Cholinergic neurotransmission (ACh precursor supply and AChE inhibition)

★★★★★Mechanism evidence: grade APrimary target

Huperzine A is a reversible, selective AChE inhibitor that can reduce acetylcholine breakdown. In healthy older adults given escalating oral doses, red blood cell AChE activity was suppressed, with inhibition above 50% after the last 200 μg dose. But changes in peripheral enzyme activity do not equal quantitative changes in synaptic acetylcholine in the brain, and the latter has not been measured directly in humans.

References (2)
  1. Gordon 2005 · Escalating oral dosing study in healthy older adults: red blood cell AChE activity was suppressed, with inhibition above 50% after the last 200 μg dose
  2. Cheng 1992 · In vitro study: huperzine A binds reversibly to mammalian AChE, with a Ki of about 20–40 nM

GABA and glutamate balance (inhibitory and excitatory tone)

★☆☆☆☆Mechanism evidence: grade DSecondary target

In vitro, huperzine A can block the NMDA channel, with an apparent Ki of about 6 μM. After a single 400 μg oral dose in humans, peak plasma concentration was only about 2.59 ng/mL, or about 11 nM. Brain concentration has not been measured directly, and an NMDA-blocking effect at usual doses has not been confirmed.

References (2)
  1. Gordon 2001 · In vitro NMDA channel binding assay: apparent Ki of about 6 μM
  2. Li 2007 · Human pharmacokinetic study: after a single 400 μg oral dose, peak plasma concentration was about 2.59 ng/mL, or about 11 nM

Safety and drug interactions

Contraindicated in epilepsy, severe bradycardia (sinus bradycardia), mechanical intestinal obstruction or active bronchial asthma. Use with other cholinesterase inhibitors or cholinergic drugs may increase adverse effects. Never double the dose or take more than the stated dose on your own.
Open in the interactive app ›